Develops food-grade Binding Proteins made by precision fermentation that neutralize harmful metabolites in the gut.
Founders
Mads Laustsen(Denmark · ♂)— A career in industrial biomanufacturing of enzymes and therapeutic proteins led him to co-found Bactolife with his son after a 2016 family vacation where they realized his manufacturing experience could scale his son's protein research.
Andreas H. Laustsen-Kiel(Denmark · ♂)— His academic research on toxin-neutralizing binding proteins, combined with his father's industrial biomanufacturing expertise, became the scientific foundation of Bactolife.
Sandra Wingaard Thrane(Denmark · ♀)— Her microbiology expertise was brought in by the Laustsens to help build Bactolife's binding-protein platform, where she became Chief Scientific Officer.
In the network
Shares the most investors with (number = shared investors):
Danish Bactolife raised over €30 million in a Series B led by Cross Border Impact Ventures and EIFO to move from R&D to commercialization, with its first US launch in 2026.
$34.8M
Aug 2023
Series A
Copenhagen-based Bactolife raised a EUR30M Series A led by ATHOS, with the Gates Foundation and Novo Holdings.
$32.4M
Aug 2022
Grant
Copenhagen gut-health biotech Bactolife secured 5M dollars from the Bill & Melinda Gates Foundation to develop its Binding Proteins against gut infections.
$5M
Investors
Tap an investor to see what else they have backed.